butorphanol tartrate

Also found in: Dictionary, Acronyms.
Related to butorphanol tartrate: Stadol

butorphanol tartrate

APO-Butorphanol (CA), PMS-Butorphanol (CA), Stadol

Pharmacologic class: Opioid agonist-antagonist

Therapeutic class: Opioid analgesic

Controlled substance schedule IV Pregnancy risk category C


Alters perception of and emotional response to pain by binding with opioid receptors in brain, causing CNS depression. Also exerts antagonistic activity at opioid receptors, which reduces risk of toxicity, drug dependence, and respiratory depression.


Injection: 1 mg/ml, 2 mg/ml

Nasal spray: 10 mg/ml

Indications and dosages

Moderate to severe pain

Adults: 1 to 4 mg I.M. q 3 to 4 hours as needed, not to exceed 4 mg/dose. Or 0.5 to 2 mg I.V. q 3 to 4 hours as needed. With nasal spray, 1 mg (one spray in one nostril) q 3 to 4 hours, repeated in 60 to 90 minutes if needed.

Labor pains

Adults: 1 to 2 mg I.V. or I.M., repeated after 4 hours as needed

Preoperative anesthesia

Adults: 2 mg I.M. 60 to 90 minutes before surgery

Balanced anesthesia

Adults: 2 mg I.V. shortly before anesthesia induction, or 0.5 to 1 mg I.V. in increments during anesthesia

Dosage adjustment

• Renal or hepatic impairment
• Elderly patients

Off-label uses

• Headache
• Symptomatic relief of ureteral colic


• Hypersensitivity to drug


Use cautiously in:
• head injury, ventricular dysfunction, coronary insufficiency, respiratory disease, renal or hepatic dysfunction
• history of drug abuse.


• Make sure solution is clear and free of particulates before giving.
• When using nasal spray, insert tip of the sprayer about ¼″ into nostril, point tip backwards, and administer one spray.
• Be aware that I.V. route is preferred for severe pain.

Know that drug may cause infant respiratory distress in neonate of pregnant patient, especially if given within 2 hours of delivery.

butorphanol tartrate

an agonist/antagonist opioid of the phenanthrene family.
indications It is administered parentally for surgical premedication, as an analgesic component of balanced anesthesia, for prompt relief of moderate to severe pain associated with surgical procedures, and as a nasal spray for the relief of migraine pain.
contraindications Butorphanol tartrate is not given to patients known to be sensitive to phenanthrenes or to persons dependent on opioids because it may provoke withdrawal symptoms.
adverse effects Toxicity may result from the use of butorphanol with other opioids.

butorphanol tartrate

a synthetic opioid with both agonist and antiagonist activities. It is used as an analgesic and antitussive.
References in periodicals archive ?
This study demonstrated intranasal butorphanol tartrate has rapid absorption and predictable accumulation after multiple dosing using unit dose, metered spray pumps.
For the IV study, anesthesia was induced and maintained with isoflurane (delivered in oxygen at 1 L/min via facemask) administered at 5% and 2%, respectively, to facilitate administration of butorphanol tartrate 1% (5 mg/kg; Torbugesic) in the basilic vein.
A standard curve of butorphanol tartrate (Cerilliant Corp, Round Rock, TX, USA), which bracketed the range of concentration, was prepared by spiking 100 [micro]L of blank parrot plasma.
To our knowledge, this is the first published study presenting the pharmacokinetic analysis of butorphanol tartrate in a psittacine species as well as the first study presenting pharmacokinetic analysis of butorphanol after oral administration in any avian species.
Our results in Hispaniolan Amazon parrots show that butorphanol tartrate has high bioavailability and rapid elimination after IM administration in contrast to low bioavailability following PO administration.
Serum concentrations and analgesic effects of liposome-encapsulated and standard butorphanol tartrate in parrots.
Birds were randomly assigned to receive butorphanol tartrate (2 mg/kg in the pectoral muscle; Torbugesic, Fort Dodge, Fort Dodge, IA, USA) either 20 minutes before induction of anesthesia with sevoflurane (B-S group, n = 11) or immediately after the anesthetic period (S group, n = 11).
Butorphanol tartrate nasal spray administered on an outpatient basis can be an important part of an effective pain management plan, Abboud said.
The efficacy, rapid onset, convenient administration and moderate sedative properties of butorphanol tartrate nasal spray make it an important alternative to oral opioid analgesics for the outpatient management of pain.